-
Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer
Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO). Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has…
-
Avisa Diagnostics to Participate at Upcoming Investor Events
Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, announced today that the Company will participate in several virtual investor events in July. David S. Joseph, President and Chief Executive Officer of Avisa, will give a company presentation at the events listed below. Investors interested in participating in any of the events can register using the links provided. Replays of the live events will be made available on the Avisa website in the Investors section. Renmark Virtual Non-Deal Roadshow July 9, 2021, 12pm ET Register here: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-cse-avbt-2021-07-09-120000 Renmark Virtual Non-Deal Roadshow…
-
Avisa Diagnostics Appoints G. Michael Landis as Chief Financial Officer
Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, is pleased to announce that G. Michael Landis has joined Avisa as Chief Financial Officer, effective immediately. Matthew Culler, who has led the company through the merger with Fogchain Corp and the listing on the Canadian Securities Exchange, will remain with Avisa as an advisor during a transition period. G. Michael Landis has over 25 years of finance and accounting experience in a variety of industries and has strong public company expertise, including the areas of capital…
-
Avisa Diagnostics to Participate in Renmark’s Virtual Non-Deal Roadshow Series on June 17, 2021
Avisa Diagnostics Inc. (CSE: AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, announced today that the Company will participate in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series on June 17, 2021 at 12:00 PM ET. Avisa Diagnostics’ President and CEO, David S. Joseph, will give a company presentation, followed by a live Q&A session. Investors interested in participating in this event will need to register using the link below. Registration for the live event may be limited, but access to a replay after the live event…
-
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange
. – Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ – Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 “long haulers,” who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality. The public listing…
